Antiviral Activity of the new DAAs for the Treatment of Hepatitis C Virus Infection: Virology and Resistance

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue , 2011, Pages S46-S51

  Chevaliez, Stéphane ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; HEPATITIS C; HUMAN; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS C, CHRONIC; HUMANS; PROTEASE INHIBITORS;

MLCS; MLOWN;

EID: 84862752785     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(11)70007-9     Document Type: Article

References (43)

1. Swain, M.G., Lai, M.Y., Shiffman, M.L., Cooksley, W.G., Zeuzem, S., Dieterich, D.T., et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139 (2010), 1593–1601.
2. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gonçales, F.L. Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002), 975–982.
3. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001), 958–965.
4. Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T., et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 130 (2006), 1086–1097.
5. Buti, M., Lurie, Y., Zakharova, N.G., Blokhina, N.P., Horban, A., Teuber, G., et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 52 (2010), 1201–1207.
6. Pearlman, B.L., Ehleb en, C., Saifee, S., Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 46 (2007), 1688–1694.
7. Sánchez-Tapias, J.M., Diago, M., Escartín, P., Enríquez, J., Romero-Gómez, M., Bárcena, R., et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131 (2006), 451–460.
8. Huang, C.F., Yang, J.F., Dai, C.Y., Huang, J.F., Hou, N.J., Hsieh, M.Y., et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis 201 (2010), 751–759.
9. Jacobson, I.M., Brown, R.S. Jr, McCone, J., Black, M., Albert, C., Dragutsky, M.S., et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 46 (2007), 982–990.
10. Pawlotsky, J.M., The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140 (2011), 746–754.
11. Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
12. Poordad, F., McCone, J. Jr, Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
13. Reesink, H.W., Zeuze m, S., Weegink, C.J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006), 997–1002.
14. Sarrazin, C., Kieff er, T.L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132 (2007), 1767–1777.
15. Forestier, N., Rees ink, H.W., Weegink, C.J., McNair, L., Kieffer, T.L., Chu, H.M., et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 46 (2007), 640–648.
16. Malcolm, B.A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 50 (2006), 1013–1020.
17. Sarrazin, C., Rouzi er, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S.K., et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 132 (2007), 1270–1278.
18. Pawlotsky, J.M., The rapeutic implications of hepatitis C virus resistance to antiviral drugs. Therap Adv Gastroenterol 2 (2009), 205–219.
19. Pawlotsky, J.M., Hep atitis, C., virus population dynamics during infection. Curr Top Microbiol Immunol 299 (2006), 261–284.
20. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 (1998), 103–107.
21. Guedj, J., Rong, L., Dahari, H., Perelson, A.S., A perspective on modelling hepatitis C virus infection. J Viral Hepat 17 (2010), 825–833.
22. Duffy, S., Shackelton, L.A., Holmes, E.C., Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 9 (2008), 267–276.
23. Pawlotsky, J.M., Treatment failure and resistance with directacting antiviral drugs against hepatitis C virus. Hepatology 53 (2011), 1742–1751.
24. Services, U.D.o.H.H., Advisory Comittee Briefing Document for NDA 201–917.
25. Telaprevir 375 mg tablets, F.a.D. Administration, Editor 2011.
26. Zeuzem, S., Barnard, R.J., Howe, J.A., Ogert, R.A., Ralston, R., Boparai, N., et al. Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alpha-2b/ribavirin (Abstract). J Hepatol 54:Suppl 1 (2011), S4–S5.
27. Susser, S., Welsch, C., Wang, Y., Zettler, M., Domingues, F.S., Karey, U., et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50 (2009), 1709–1718.
28. Metzker, M.L., Seque ncing technologies -the next generation. Nat Rev Genet 11 (2010), 31–46.
29. Chevaliez, S., Rodr iguez, C., Soulier, A., Ahmed-Belkacem, A., Hézode, C., Pawlotsky, J.M., Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations (Abstract). J Hepatol, 54(Suppl 1), 2011, S30.
30. Verbinnen, T., Van Marck, H., Vandenbroucke, I., Vijgen, L., Claes, M., Lin, T.I., et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol 84 (2010), 11124–11133.
31. Adiwijaya, B.S., Herrmann, E., Hare, B., Kieffer, T., Lin, C., Kwong, A.D., et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol, 6, 2010, e1000745.
32. Kieffer, T.L., Sarra zin, C., Miller, J.S., Welker, M.W., Forestier, N., Reesink, H.W., et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46 (2007), 631–639.
33. Tong, X., Arasappan, A., Bennett, F., Chase, R., Feld, B., Guo, Z., et al. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob Agents Chemother 54 (2010), 2365–2370.
34. Lin, K., Kwong, A.D., Lin, C., Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 48 (2004), 4784–4792.
35. Hézode, C., Foresti er, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009), 1839–1850.
36. Kwo, P.Y., Lawitz, E.J., McCone, J., Schiff, E.R., Vierling, J.M., Pound, D., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376 (2010), 705–716.
37. McHutchison, J.G., Everson, G.T., Gordon, S.C., Jacobson, I.M., Sulkowski, M., Kauffman, R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009), 1827–1838.
38. McHutchison, J.G., Manns, M.P., Muir, A.J., Terrault, N.A., Jacobson, I.M., Afdhal, N.H., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 362 (2010), 1292–1303.
39. Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1207–1217.
40. Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 364 (2011), 2417–2428.
41. Susser, S., Vermehr en, J., Forestier, N., Welker, M.W., Grigorian, N., Füller, C., et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 52 (2011), 321–327.
42. Sullivan, J.C., De, M., eyer, S., Bartels, D.J., Dierynck, I., Zhang, E., Spanks, J., et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials (Abstract). J Hepatol, 54(Suppl 1), 2011, S4.
43. Sherman, K.E., Sulkowski, M.S., Zoulim, F., Alberti, A., Wei, L.J., Sullivan, J., et al. Follow-up of SVR durability and viral reistance in patients with chronic hepatitis C treated with telaprevir-based regimpens: interim analysis of the EXTEND study (Abstract). Hepatology 54:Suppl 1 (2011), 485–486A.